Avacta Group
Unaudited interim results for the six months ended 30 June 2024 have been released. In terms of financials these provided little in the way of surprises, while the Board continued to stress the exceptional progress being made with its drug development candidate AVA6000, along with a high level of confidence in the capabilities of its pre|CISION™ platform. Second and third generation programs have already been designed to leverage the platform as a foundation for other tumour-specific warhead delivery systems across an innovative pipeline. More details on these will be provided when the Group hosts a live R&D Spotlight: Next Generation of pre|CISION™ Medicines in London on 30 October 2024.

